I-Mab (IMAB) 6-K: Givastomig data presentation on Oct 23, 2025

I-Mab furnished a Form 6-K announcing it will present positive updated data for its Givastomig monotherapy at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025.

Rhea-AI Filing Summary

I-Mab furnished a Form 6-K announcing it will present positive updated data for its Givastomig monotherapy at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025.

Exhibit 99.1, a press release with these details, is incorporated by reference into the company’s existing registration statements on Forms F-3 and S-8.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IMAB disclose in this Form 6-K?

The company will present positive updated Givastomig monotherapy data at the 2025 AACR-NCI-EORTC conference on October 23, 2025, detailed in Exhibit 99.1.

When is I-Mab’s Givastomig presentation scheduled?

October 23, 2025, at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.

What is Exhibit 99.1 in IMAB’s 6-K?

A press release titled “I-Mab To Present Positive Updated Givastomig Monotherapy Data” related to the October 23, 2025 conference.

Are the materials incorporated by reference?

Yes. Exhibit 99.1 is incorporated by reference into the company’s existing registration statements on Forms F-3 and S-8.

Who signed the report for IMAB?

Chief Executive Officer Xi-Yong (Sean) Fu signed the report.

What period does this 6-K cover?

It is for the month of October 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/22/2025 - 12:38 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39173

I-MAB

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

DOCUMENTS INCORPORATED BY REFERENCE

Exhibit 99.1 set forth in this Form 6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684, File No. 333-279842 and File No. 333-290195) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release - I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	I-MAB
	By	:	/s/ Xi-Yong Fu
	Name	:	Xi-Yong (Sean) Fu
	Title	:	Chief Executive Officer

Date: October 22, 2025